November 18, 2026
Health news, explained with evidence
LIVE

Blood-Based Fibrosis Scores Align With Liver Stiffness in Type 2 Diabetes

🧠 AI Analysis 2 min read 👁 5

A cross-sectional analysis indicates that specific blood-based fibrosis scores correlate with liver stiffness measurements in adults managing type 2 diabetes.

🧠AI Analysis

Key points

  • Evaluated 18 liver scores against ultrasound imaging in 40 adults with type 2 diabetes
  • Found notable positive correlations between blood-based fibrosis scores and liver stiffness
  • Reinforces guideline-recommended, two-step risk stratification approaches for liver fibrosis

An exploratory cross-sectional study published in Nature Health Sciences evaluated associations between blood-based fibrosis scoring systems and ultrasound-derived liver assessments in adults living with type 2 diabetes mellitus and suspected liver involvement. Conducted by researchers across academic medical centers in Prague, the study analyzed data from 40 participants to see how various circulating biomarkers and calculated indexes align with imaging markers of metabolic dysfunction-associated steatotic liver disease.

The investigation examined 18 different liver scores alongside body composition metrics and circulating biomarkers, comparing them against two-dimensional shear-wave elastography, shear-wave dispersion, and attenuation imaging. Out of these evaluations, multiple fibrosis-oriented scores demonstrated positive correlations with two-dimensional shear-wave elastography after adjusting for false discovery rates. Specifically, the DiabetesLiver score showed a notable positive coefficient, closely followed by the widely recognized Fibrosis-4 Index. Additional measures, including the Enhanced Liver Fibrosis test and LiverRisk, also displayed significant correlations with liver stiffness.

The authors noted important limitations, emphasizing that moderate associations with liver stiffness do not establish diagnostic equivalence. Furthermore, the limited statistical power due to the sample size warrants caution when interpreting the wider biomarker data. These results align with guideline-recommended, two-step risk stratification strategies for advanced liver fibrosis in metabolic dysfunction-associated steatotic liver disease, which typically begin with a Fibrosis-4 Index before proceeding to targeted liver stiffness measurements or further biomarker panels.

What to know: Adults managing type 2 diabetes face an elevated risk of liver complications like metabolic dysfunction-associated steatotic liver disease. While blood scores offer helpful preliminary risk estimates, they require validation through imaging or clinical testing. Always talk to a doctor for personal medical decisions and individualized care strategies.

Source Nature Health Sciences — nature.com/articles/s41598-026-79225-3 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.